Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
NCT06932809
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Tauopathies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Pennsylvania
- Last updated on ClinicalTrials.gov
- December 23, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California · San Francisco, CA
Pennsylvania · 1
- University of Pennsylvania · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.